Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd > 🇮🇱COVID-19 VAX --- T-CELL FUNCTIONℹ Official Company Vid

<< Previous

Bullboard Posts

Next >>

Comment by PowerofNowon Feb 19, 2021 1:59pm

84 Views

Post# 32611449

RE:🇮🇱COVID-19 VAX --- T-CELL FUNCTIONℹ Official Company Vid

Just a thought what if the animal model they used and dosage increments was not enough to activate the T-Cell memory for this study? The immune system "responded" so that's GOOD NEWS. Anyone who sold at these low numbers are gonna feel horrible when they see a new pop past 52 week high in less than 2 months.

<< Previous

Bullboard Posts

Next >>

Rick Rule’s election insights: Gold, USD, and Canadian gas